Literature DB >> 25178499

Decade in review--hypertension: the past decade in hypertension--facts, hopes, and hypes.

Thomas Unger1.   

Abstract

Hypertension research in the past decade has been a mixture of hope and hype. In the absence of new drug developments, clinical intervention procedures such as renal nerve ablation and baroreflex activation therapy have dominated the research, but the results have not yet fulfilled the great expectations.

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25178499     DOI： 10.1038/nrcardio.2014.131

Source DB:  PubMed          Journal:  Nat Rev Cardiol        ISSN： 1759-5002            Impact factor:   32.419


  9 in total

1.  Baroreflex activation therapy lowers blood pressure in patients with resistant hypertension: results from the double-blind, randomized, placebo-controlled rheos pivotal trial.

Authors:  John D Bisognano; George Bakris; Mitra K Nadim; Luis Sanchez; Abraham A Kroon; Jill Schafer; Peter W de Leeuw; Domenic A Sica
Journal:  J Am Coll Cardiol       Date:  2011-08-09       Impact factor: 24.094

2.  T regulatory lymphocytes prevent angiotensin II-induced hypertension and vascular injury.

Authors:  Tlili Barhoumi; Daniel A Kasal; Melissa W Li; Layla Shbat; Pascal Laurant; Mario F Neves; Pierre Paradis; Ernesto L Schiffrin
Journal:  Hypertension       Date:  2011-01-24       Impact factor: 10.190

3.  H2S as a physiologic vasorelaxant: hypertension in mice with deletion of cystathionine gamma-lyase.

Authors:  Guangdong Yang; Lingyun Wu; Bo Jiang; Wei Yang; Jiansong Qi; Kun Cao; Qinghe Meng; Asif K Mustafa; Weitong Mu; Shengming Zhang; Solomon H Snyder; Rui Wang
Journal:  Science       Date:  2008-10-24       Impact factor: 47.728

4.  Telmisartan, ramipril, or both in patients at high risk for vascular events.

Authors:  Salim Yusuf; Koon K Teo; Janice Pogue; Leanne Dyal; Ingrid Copland; Helmut Schumacher; Gilles Dagenais; Peter Sleight; Craig Anderson
Journal:  N Engl J Med       Date:  2008-03-31       Impact factor: 91.245

5.  Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial.

Authors:  S Yusuf; K Teo; C Anderson; J Pogue; L Dyal; I Copland; H Schumacher; G Dagenais; P Sleight
Journal:  Lancet       Date:  2008-08-29       Impact factor: 79.321

6.  Effect of immunisation against angiotensin II with CYT006-AngQb on ambulatory blood pressure: a double-blind, randomised, placebo-controlled phase IIa study.

Authors:  Alain C Tissot; Patrik Maurer; Juerg Nussberger; Robert Sabat; Thomas Pfister; Stanislav Ignatenko; Hans-Dieter Volk; Hans Stocker; Philipp Müller; Gary T Jennings; Frank Wagner; Martin F Bachmann
Journal:  Lancet       Date:  2008-03-08       Impact factor: 79.321

7.  A controlled trial of renal denervation for resistant hypertension.

Authors:  Deepak L Bhatt; David E Kandzari; William W O'Neill; Ralph D'Agostino; John M Flack; Barry T Katzen; Martin B Leon; Minglei Liu; Laura Mauri; Manuela Negoita; Sidney A Cohen; Suzanne Oparil; Krishna Rocha-Singh; Raymond R Townsend; George L Bakris
Journal:  N Engl J Med       Date:  2014-03-29       Impact factor: 91.245

8.  Genome-wide association study identifies eight loci associated with blood pressure.

Authors:  Christopher Newton-Cheh; Toby Johnson; Vesela Gateva; Martin D Tobin; Murielle Bochud; Lachlan Coin; Samer S Najjar; Jing Hua Zhao; Simon C Heath; Susana Eyheramendy; Konstantinos Papadakis; Benjamin F Voight; Laura J Scott; Feng Zhang; Martin Farrall; Toshiko Tanaka; Chris Wallace; John C Chambers; Kay-Tee Khaw; Peter Nilsson; Pim van der Harst; Silvia Polidoro; Diederick E Grobbee; N Charlotte Onland-Moret; Michiel L Bots; Louise V Wain; Katherine S Elliott; Alexander Teumer; Jian'an Luan; Gavin Lucas; Johanna Kuusisto; Paul R Burton; David Hadley; Wendy L McArdle; Morris Brown; Anna Dominiczak; Stephen J Newhouse; Nilesh J Samani; John Webster; Eleftheria Zeggini; Jacques S Beckmann; Sven Bergmann; Noha Lim; Kijoung Song; Peter Vollenweider; Gerard Waeber; Dawn M Waterworth; Xin Yuan; Leif Groop; Marju Orho-Melander; Alessandra Allione; Alessandra Di Gregorio; Simonetta Guarrera; Salvatore Panico; Fulvio Ricceri; Valeria Romanazzi; Carlotta Sacerdote; Paolo Vineis; Inês Barroso; Manjinder S Sandhu; Robert N Luben; Gabriel J Crawford; Pekka Jousilahti; Markus Perola; Michael Boehnke; Lori L Bonnycastle; Francis S Collins; Anne U Jackson; Karen L Mohlke; Heather M Stringham; Timo T Valle; Cristen J Willer; Richard N Bergman; Mario A Morken; Angela Döring; Christian Gieger; Thomas Illig; Thomas Meitinger; Elin Org; Arne Pfeufer; H Erich Wichmann; Sekar Kathiresan; Jaume Marrugat; Christopher J O'Donnell; Stephen M Schwartz; David S Siscovick; Isaac Subirana; Nelson B Freimer; Anna-Liisa Hartikainen; Mark I McCarthy; Paul F O'Reilly; Leena Peltonen; Anneli Pouta; Paul E de Jong; Harold Snieder; Wiek H van Gilst; Robert Clarke; Anuj Goel; Anders Hamsten; John F Peden; Udo Seedorf; Ann-Christine Syvänen; Giovanni Tognoni; Edward G Lakatta; Serena Sanna; Paul Scheet; David Schlessinger; Angelo Scuteri; Marcus Dörr; Florian Ernst; Stephan B Felix; Georg Homuth; Roberto Lorbeer; Thorsten Reffelmann; Rainer Rettig; Uwe Völker; Pilar Galan; Ivo G Gut; Serge Hercberg; G Mark Lathrop; Diana Zelenika; Panos Deloukas; Nicole Soranzo; Frances M Williams; Guangju Zhai; Veikko Salomaa; Markku Laakso; Roberto Elosua; Nita G Forouhi; Henry Völzke; Cuno S Uiterwaal; Yvonne T van der Schouw; Mattijs E Numans; Giuseppe Matullo; Gerjan Navis; Göran Berglund; Sheila A Bingham; Jaspal S Kooner; John M Connell; Stefania Bandinelli; Luigi Ferrucci; Hugh Watkins; Tim D Spector; Jaakko Tuomilehto; David Altshuler; David P Strachan; Maris Laan; Pierre Meneton; Nicholas J Wareham; Manuela Uda; Marjo-Riitta Jarvelin; Vincent Mooser; Olle Melander; Ruth J F Loos; Paul Elliott; Gonçalo R Abecasis; Mark Caulfield; Patricia B Munroe
Journal:  Nat Genet       Date:  2009-05-10       Impact factor: 38.330

9.  Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study.

Authors:  Henry Krum; Markus Schlaich; Rob Whitbourn; Paul A Sobotka; Jerzy Sadowski; Krzysztof Bartus; Boguslaw Kapelak; Anthony Walton; Horst Sievert; Suku Thambar; William T Abraham; Murray Esler
Journal:  Lancet       Date:  2009-03-28       Impact factor: 79.321
  9 in total
  3 in total

Review 1.  Qiju Dihuang Decoction for Hypertension: A Systematic Review and Meta-Analysis.

Authors:  Shuo Zhang; Xue Bai; Zhen-Lin Chen; Jia-Jia Li; Yan-Yan Chen; Yu-Ping Tang
Journal:  Evid Based Complement Alternat Med       Date:  2020-07-31       Impact factor: 2.629

2.  Meta-analysis of the effectiveness of traditional Chinese herbal formula Zhen Wu Decoction for the treatment of hypertension.

Authors:  Xingjiang Xiong; Pengqian Wang; Shengjie Li
Journal:  BMJ Open       Date:  2015-12-11       Impact factor: 2.692

3.  Therapeutic Efficacy and Safety of Traditional Chinese Medicine Classic Herbal Formula Longdanxiegan Decoction for Hypertension: A Systematic Review and Meta-Analysis.

Authors:  Xing-Jiang Xiong; Xiao-Chen Yang; Wei Liu; Lian Duan; Peng-Qian Wang; Hu You; Xiao-Ke Li; Shihan Wang
Journal:  Front Pharmacol       Date:  2018-05-08       Impact factor: 5.810
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.